SEC Company Response from Forte Biosciences, Inc. (FBRX) (CIK 0001419041) (FBRX) — May 12, 2020
Forte Biosciences, Inc. (FBRX) (CIK 0001419041)
Date: May 12, 2020 · CIK: 0001419041 · Accession: 0001193125-20-140153
AI Filing Summary & Sentiment
File numbers found in text: 333-237371
Letter
Tocagen Inc.
4445 Eastgate Mall, Suite 200
San Diego, CA 92121
(858) 412-8400
May 12, 2020
VIA EDGAR
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3628
Attention:
Julie Sherman
Brian Cascio
Courtney Lindsay
Irene Paik
Re: Request for Effectiveness for Tocagen Inc.
Registration Statement on Form S-4 (File No. 333-237371)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tocagen Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:00 p.m. Eastern Time, on May 13, 2020, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Karen Deschaine of Cooley LLP of such effectiveness by telephone at (858) 550-6088.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Deschaine at the telephone number above.
Very truly yours,
Tocagen Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Tocagen Inc. 4445 Eastgate Mall, Suite 200 San Diego, CA 92121 (858) 412-8400 May 12, 2020 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Julie Sherman Brian Cascio Courtney Lindsay Irene Paik Re: Request for Effectiveness for Tocagen Inc. Registration Statement on Form S-4 (File No. 333-237371) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tocagen Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:00 p.m. Eastern Time, on May 13, 2020, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Karen Deschaine of Cooley LLP of such effectiveness by telephone at (858) 550-6088. If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Deschaine at the telephone number above. Very truly yours, Tocagen Inc. By: /s/ Mark Foletta Name: Mark Foletta Title: Chief Financial Officer cc: Karen Deschaine, Cooley LLP